A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells - Wikidata - wikimedia - TriplyDB

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

http://www.wikidata.org/entity/Q35132029

about

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site Second- and third-generation ALK inhibitors for non-small cell lung cancer Second-generation inhibitors of Bruton tyrosine kinase Improving natural killer cell cancer immunotherapy A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development."NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.Harnessing NK Cell Memory for Cancer Immunotherapy.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Acute myeloid leukemia targets for bispecific antibodies.The making of bispecific antibodies Detection of a phosphorylated glycine-serine linker in an IgG-based fusion protein.A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Bispecific antibodies in cancer immunotherapy.Development of a bispecific antibody tetramerized through hetero-associating peptides.Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.Tumor immunotherapy: New aspects of natural killer cells.Bispecific antibodies in cancer immunotherapy

P2860

Q26785828-A5A85643-8693-4300-8A72-1EA6A1DF5063 Q28066935-E0EB318A-7185-468E-A6F6-DBE5CDCA5CE6 Q28072496-A2913B54-A968-404C-8B08-AC1A7B1CB4FF Q28076118-78A36AF1-9385-4E72-BFA2-14B9F066D449 Q28087719-B5C52076-6D18-48E2-8DD5-637BD6899A8A Q34221898-FA9C4567-8813-48CA-A447-F85A23DA05F7 Q34548319-19FD728B-7101-4944-B5E1-E755450A7CFE Q34550963-1D70CB8E-54AA-4517-A52A-6DED8993F33D Q35871726-E8D61A8A-1283-4B93-AC41-937E41953CC1 Q35925674-C0F02EFA-9790-4EB9-B440-2AFB0FE83140 Q37129564-69E4311C-F69E-4C1E-B050-37D17DF67C80 Q38558611-52784976-F892-4FC2-8780-257B21D12247 Q38640917-7BC480EC-DB5C-401D-B78B-C4B5F9FE0AF4 Q38723957-6B99530C-613D-46C1-AF15-A4BD33897CFB Q38988913-D2481F59-8732-4304-8CB2-01FE5477A1FA Q38989496-48B9B811-5D2A-4555-8312-127E111892B7 Q39117761-B2969811-68DD-49D7-A5F2-12773BF3947F Q42323236-2FBEEEDD-A64C-4B3D-93AA-E1B66059D847 Q42330118-B005645E-C858-4A3A-A3D2-EDC4EA86D771 Q42601428-FA7A7214-BE58-45EC-BF47-F5C45C931B33 Q42660142-31E50850-2A0F-4E46-87F1-ECDBA83E9D63 Q51309023-041F93B4-44B7-4725-A88B-113916E8DE44 Q51784482-0484CB79-05FB-4D56-A385-9C274F2DB19E Q52680552-6CEAE925-1DF3-4E34-8652-F97A9A8BD142 Q55107050-BC94D8F1-F875-4511-B32D-7A32FA1CDFDB Q56893015-B2E1D9C0-ADA6-42EC-AA7A-4BAF7B8BFE1D

P2860

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

http://www.wikidata.org/entity/Q35132029

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A novel tetravalent bispecific ...... the lysis of CD30+ tumor cells

@ast

A novel tetravalent bispecific ...... the lysis of CD30+ tumor cells

@en

type

label

A novel tetravalent bispecific ...... the lysis of CD30+ tumor cells

@ast

A novel tetravalent bispecific ...... the lysis of CD30+ tumor cells

@en

prefLabel

A novel tetravalent bispecific ...... the lysis of CD30+ tumor cells

@ast

A novel tetravalent bispecific ...... the lysis of CD30+ tumor cells

@en

P1433

Q35132029-F14041A8-FFBB-4365-931D-D3566022F3D9

P1476

Q35132029-5ADBBFAF-70C7-4937-B0F4-5CF8CAE719CE

P2093

Q35132029-1990A09A-1EA7-4AC7-80B2-8E8A349F9B35

Q35132029-1D7D0BD4-B172-42FC-AA99-6C59D816AC9D

Q35132029-392ABE0C-708E-482E-A101-5828AD74359B

Q35132029-794B11CE-B7E9-45B2-846A-C567DD45622F

Q35132029-80C63E07-F16E-47E4-8D84-92B2A119F8BF

Q35132029-8B5DE7AC-D998-44E9-860D-70B1963725A2

Q35132029-B11CD6E9-D4DE-4982-B5BD-238CB6F0DDE8

Q35132029-C9A873E5-56E6-4A9C-B579-E2E94CA75A56

Q35132029-CFB82C14-C0C8-49AE-A562-A18BD939B721

Q35132029-FE9A3608-0071-4DC1-9FC8-DEAB3E9FA218

P2860

Q35132029-11DB8828-9776-4EB4-A2EE-7A21F20ED125

Q35132029-1FF81E21-7AC5-4C87-A8DE-0954234B2271

Q35132029-30266E88-A949-49D3-8A7B-83AFF9E6FAAA

Q35132029-303F41F6-8128-43FE-80E0-46BCC3CB20EE

Q35132029-35BD9D6D-330B-4C84-8B6F-B233F2A6F5D9

Q35132029-371FF6D0-403F-4BF7-8344-2F2D80D218C5

Q35132029-47EAC165-B588-4E72-BB8D-208C5F74BB06

Q35132029-481DE5FF-80C4-4F97-81AD-C0AF8197FCC2

Q35132029-4DD75966-0E8B-4B7B-B640-8E2CA4CBD867

Q35132029-53149874-AD29-46AA-B14B-FA7B28FA6CD1

P304

Q35132029-CDC2A377-17D7-4EA5-9BE8-4FEA96B9DAAE

P31

Q35132029-A943DB39-4278-4D5F-A576-B589B7FAE816

P356

Q35132029-41710650-BB1F-4742-8A37-C1806831B385

P433

Q35132029-394E8270-D2A3-4B00-9055-9A15483A7370

P478

Q35132029-4F9D9D33-9B9A-4912-AF91-E9EE70AAB2C3

P577

Q35132029-6614896D-77DF-4AFC-A373-90ABE30AEC77

P5875

Q35132029-0CAFA9E7-9595-4222-8266-5DA15A92B542

P698

Q35132029-C3CA9F81-4441-4062-8345-5101B15B5BC7

P932

Q35132029-3123E8D2-99F6-4127-962A-ADA3A6347C7C

P356

P1433

Monoclonal Antibodies

P1476

A novel tetravalent bispecific ...... the lysis of CD30+ tumor cells

@en

P2093

Carmen Burkhardt

http://www.w3.org/2001/XMLSchema#string

Eugene A Zhukovsky

http://www.w3.org/2001/XMLSchema#string

Fabrice Le Gall

http://www.w3.org/2001/XMLSchema#string

Ivica Fucek

http://www.w3.org/2001/XMLSchema#string

Karin Hoffmann

http://www.w3.org/2001/XMLSchema#string

Melvyn Little

http://www.w3.org/2001/XMLSchema#string

Mikaelle Le Gall

http://www.w3.org/2001/XMLSchema#string

Sergej Kiprijanov

http://www.w3.org/2001/XMLSchema#string

Stefan H J Knackmuss

http://www.w3.org/2001/XMLSchema#string

Uwe Reusch

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of polymorphic forms of Fc receptor III on human neutrophils.

Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells.

Immunotherapeutic perspective for bispecific antibodies.

Engineered antibody Fc variants with enhanced effector function.

The biology of human natural killer-cell subsets.

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity.

The biology of Hodgkin's lymphoma.

Biology and clinical relevance of human natural killer cells.

P304

728-739

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.28591

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261138071

http://www.w3.org/2001/XMLSchema#string

P698

24670809

http://www.w3.org/2001/XMLSchema#string

P932

4011917

http://www.w3.org/2001/XMLSchema#string